American Journal of Cardiology
Volume 103, Issue 8 , Pages 1056-1060 , 15 April 2009

Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)

  • Patricia Tung, MD, MPP

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • Stephen D. Wiviott, MD

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-278-0145; fax: 617-975-0955
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • Sabina A. Murphy, MPH

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • Carolyn H. McCabe, BS

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • C. Michael Gibson, MD, MS

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts

Received 27 August 2008 ,Revised 9 December 2008 ,Accepted 9 December 2008.

  • Image Result

    Baseline LDL (LDL-C) and HDL cholesterol (HDL-C) by season.

    Baseline LDL (LDL-C) and HDL cholesterol (HDL-C) by season.

  • Image Result

    On-treatment (≥4 months) median (A) LDL cholesterol (milligrams per deciliter) and (B) HDL cholesterol (milligrams per deciliter) by season.

    On-treatment (≥4 months) median (A) LDL cholesterol (milligrams per deciliter) and (B) HDL cholesterol (milligrams per deciliter) by season.

  • Image Result

    Median percentage of decrease in LDL cholesterol (≥4 months vs baseline).

    Median percentage of decrease in LDL cholesterol (≥4 months vs baseline).

  • Image Result

    On-treatment (≥4 months) percentages achieving LDL cholesterol <100 and <70 mg/dl.

    On-treatment (≥4 months) percentages achieving LDL cholesterol <100 and <70 mg/dl.

 The PROVE IT-TIMI 22 Study was supported by a research grant from Bristol-Myers Squibb, New York, New York. Dr. Wiviott has received honoraria for speaking from Pfizer, New York, New York, and Merck and Co., Whitehouse Station, New Jersey, and consulting fees from Sanofi-Aventis, Bridgewater, New Jersey. Dr. Cannon currently receives research grants/support from Accumetrics, San Diego, California, AstraZeneca, Wilmington, Delaware, Bristol-Myers Squibb/Sanofi Partnership, New York, New York, Glaxo Smith Kline Brentford, Middlesex, United Kingdom, and Merck/Schering Plough Partnership, Kenilworth, New Jersey.

PII: S0002-9149(09)00042-3

doi: 10.1016/j.amjcard.2008.12.034

American Journal of Cardiology
Volume 103, Issue 8 , Pages 1056-1060 , 15 April 2009

Article Tools

* Image Usage & Resolution